Myeloid
Mostrando 1-12 de 1800 artigos, teses e dissertações.
-
1. Chronic myeloid leukemia developing in treated acute promyelocytic leukemia
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. Jumping translocation: an unusual cytogenetic finding in myeloid neoplasm
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
3. Megakaryocytic blast crisis in chronic myeloid leukiemia: An uncommon presentation in a common neoplasm
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
4. Teratogenic effect of decitabine in a pregnant patient with acute myeloid leukemia: a case report
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
5. Acute lymphoblastic leukemia to acute myeloid leukemia: an unusual case report of lineage switching
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
6. Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes
ABSTRACT Introduction: One of the most critical complications in myelodysplastic syndromes (MDS) is the progression to acute myeloid leukemia (AML). The dynamics of clonal evolution in MDS and how acquired mutations can be used as biomarkers to track disease progression remains under investigation. Objective and method: Herein, we investigated the frequenc
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
7. Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
ABSTRACT Introduction: Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success. Treatment discontinuation should not be proposed to the CML patient if minimum conditions are not met. In Brazil
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
8. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
9. Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA
ABSTRACT Introduction: Although several combination therapies for acute myeloid leukemia (AML) have emerged recently, there has been a lack of published surveys and educational projects focused on these important treatment options. We aimed to improve the oncology team members’ knowledge and awareness of several FDA approved combination therapies for AML,
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
10. Oral manifestations of leukemia as part of early diagnosis
ABSTRACT Introduction: The oral cavity can present the first clinical manifestations of leukemia, therefore; it is important to recognize their principal characteristics. Objective: To identify oral manifestations as the first clinical signs of leukemia. Methods: This is an integrative review, that gathered data from articles with oral manifestations of l
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
11. Acute invasive fungal rhinosinusitis in pediatric patients with oncohematological diseases
Abstract Introduction Invasive fungal diseases represent important causes of morbidity and mortality among pediatric oncohematological patients. Acute invasive fungal rhinosinusitis is a rare and aggressive disease that occurs mainly in immunocompromised patients. The mortality rate is high and therefore, accurate and early diagnosis is essential. Objectiv
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
12. Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
ABSTRACT This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and fr
Hematol., Transfus. Cell Ther.. Publicado em: 2021-06